AI技术发展迅速，引领制药领域创新变革，关注恒生生物科技ETF国泰（520933）投资价值

Group 1 - The core viewpoint of the article highlights that AI technology is driving innovation in the pharmaceutical sector, with Nvidia and Eli Lilly collaborating to establish an AI+Pharmaceutical Innovation Lab, planning to invest up to $1 billion over the next five years to enhance drug development productivity [1] - TempusAI's performance indicates that AI has a high replicability in clinical testing and the commercialization of medical data, showcasing the potential of AI in transforming the pharmaceutical industry [1] - The current phase in the pharmaceutical industry is characterized by a resonance of technological breakthroughs, active funding, and accelerated application of AI technology, pushing the industry towards a data and algorithm-driven transformation [1] Group 2 - The Hang Seng Biotechnology Index focuses on innovative drugs, highlighting three key advantages: leading companies, scarce futures, and high elasticity & high Sharpe ratio [1] - Investors looking to conveniently participate in core leading innovative drugs can consider the Hang Seng Biotechnology ETF from Guotai (520933) for a streamlined investment approach [1]